These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2001331)

  • 1. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA.
    Andrews PA; Jones JA
    Cancer Commun; 1991 Mar; 3(3):93-102. PubMed ID: 2001331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-DNA damage recognition proteins in human tumour extracts.
    Bissett D; McLaughlin K; Kelland LR; Brown R
    Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
    Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
    Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo.
    Mello JA; Lippard SJ; Essigmann JM
    Biochemistry; 1995 Nov; 34(45):14783-91. PubMed ID: 7578087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells.
    Katz EJ; Andrews PA; Howell SB
    Cancer Commun; 1990; 2(4):159-64. PubMed ID: 2114928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA.
    Yaneva J; Leuba SH; van Holde K; Zlatanova J
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13448-51. PubMed ID: 9391045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication.
    Heiger-Bernays WJ; Essigmann JM; Lippard SJ
    Biochemistry; 1990 Sep; 29(36):8461-6. PubMed ID: 2174701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines.
    Chen G; Zeller WJ
    Cancer Lett; 1992 Oct; 67(1):27-33. PubMed ID: 1423242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel protein that specifically binds to DNA modified by N-acetoxy-acetylaminofluorene and cis-diamminedichloroplatinum.
    Pietrowska M; Widłak P
    Acta Biochim Pol; 2005; 52(4):867-74. PubMed ID: 15940347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay.
    Fujiwara Y; Kasahara K; Sugimoto Y; Nishio K; Ohmori T; Saijo N
    Jpn J Cancer Res; 1990 Dec; 81(12):1210-3. PubMed ID: 2125989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.
    Guggenheim ER; Xu D; Zhang CX; Chang PV; Lippard SJ
    Chembiochem; 2009 Jan; 10(1):141-57. PubMed ID: 19053130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA binding activities of p53 protein following cisplatin damage of ovarian cells.
    Wetzel CC; Berberich SJ
    Oncol Res; 1998; 10(3):151-61. PubMed ID: 9700726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
    Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
    Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells.
    Chen G; Zeller WJ
    Anticancer Res; 1994; 14(4A):1461-7. PubMed ID: 7979172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.